RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.

Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.